A detailed history of Dimensional Fund Advisors LP transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Dimensional Fund Advisors LP holds 501,569 shares of NRIX stock, worth $9.82 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
501,569
Previous 603,133 16.84%
Holding current value
$9.82 Million
Previous $12.6 Million 10.54%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$18.93 - $25.69 $1.92 Million - $2.61 Million
-101,564 Reduced 16.84%
501,569 $11.3 Million
Q2 2024

Aug 09, 2024

SELL
$12.02 - $21.3 $4.37 Million - $7.74 Million
-363,320 Reduced 37.59%
603,133 $12.6 Million
Q1 2024

May 10, 2024

SELL
$7.77 - $15.66 $261,002 - $526,035
-33,591 Reduced 3.36%
966,453 $14.2 Million
Q4 2023

Feb 07, 2024

BUY
$4.25 - $10.71 $178,504 - $449,830
42,001 Added 4.38%
1,000,044 $10.3 Million
Q3 2023

Nov 09, 2023

BUY
$7.86 - $10.08 $1.42 Million - $1.82 Million
180,531 Added 23.22%
958,043 $7.53 Million
Q2 2023

Aug 09, 2023

BUY
$8.7 - $13.28 $1.25 Million - $1.91 Million
143,995 Added 22.73%
777,512 $7.77 Million
Q1 2023

May 12, 2023

BUY
$8.56 - $13.26 $426,074 - $660,016
49,775 Added 8.53%
633,517 $5.63 Million
Q4 2022

Feb 09, 2023

BUY
$9.86 - $14.59 $2.46 Million - $3.63 Million
249,017 Added 74.39%
583,742 $6.41 Million
Q3 2022

Nov 10, 2022

BUY
$12.33 - $19.81 $1.61 Million - $2.58 Million
130,423 Added 63.84%
334,725 $4.36 Million
Q2 2022

Aug 12, 2022

SELL
$7.88 - $14.82 $261,797 - $492,364
-33,223 Reduced 13.99%
204,302 $2.59 Million
Q1 2022

May 13, 2022

BUY
$12.94 - $29.65 $1.57 Million - $3.59 Million
121,167 Added 104.13%
237,525 $3.33 Million
Q4 2021

Feb 09, 2022

BUY
$26.43 - $34.5 $3.08 Million - $4.01 Million
116,358 New
116,358 $3.37 Million

Others Institutions Holding NRIX

About Nurix Therapeutics, Inc.


  • Ticker NRIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,147,800
  • Market Cap $923M
  • Description
  • Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...
More about NRIX
Track This Portfolio

Track Dimensional Fund Advisors LP Portfolio

Follow Dimensional Fund Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Dimensional Fund Advisors LP with notifications on news.